$0.68
-0.07 (-8.81%)
Open$0.77
Previous Close$0.75
Day High$0.80
Day Low$0.65
52W High$2.55
52W Low$0.56
Volume—
Avg Volume243.0K
Market Cap24.66M
P/E Ratio—
EPS$-3.59
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,713.7% upside
Current
$0.68
$0.68
Target
$12.42
$12.42
$7.12
$12.42 avg
$14.14
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 33.65M | 29.55M | 10.25M |
| Net Income | -116,252,241 | -91,874,795 | 2.27M |
| Profit Margin | -345.5% | -328.2% | 22.1% |
| EBITDA | -90,496,281 | -75,493,033 | 3.06M |
| Free Cash Flow | — | — | 1.07M |
| Rev Growth | +13.9% | +13.9% | +24.9% |
| Debt/Equity | 4.75 | 4.75 | 0.86 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |